R01HL160921

Hyperglycemia and Adverse Pregnancy Outcome Study-Cardiovascular Health of HAPO Offspring (HAPO CVH) - Project Summary

Halting the intergenerational transfer of cardiovascular disease (CVD) risk is a priority for NHLBI and the American Heart Association (AHA). Yet, limited understanding around the timing, pathways, and mechanisms underlying the observed associations between maternal gestational health and offspring cardiovascular health (CVH) remains a significant barrier to developing targeted, timely interventions.

We propose to leverage the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study cohort to substantially advance understanding of the in utero origins of offspring CVH and CVD, as measured during the critical period of young adulthood. The original HAPO study recruited ~25,500 women in 2000-2006 to prospectively and uniformly examine the association of gestational glycemia, uncomplicated by treatment, with maternal and neonatal outcomes. Eleven years later, 4,832 offspring returned to study effects of GDM on offspring adiposity and glycemia.

We hypothesize that there are significant independent associations of maternal adiposity, glycemia, blood pressure, and lipids at ~28 weeks gestation with CVH and arterial injury among offspring at age 18-25 years, and that DNA methylation (DNAm) will be associated with upstream intrauterine exposures and downstream CVH and arterial injury.

HAPO CVH will include a comprehensive CVH assessment of 1,000 HAPO FUS offspring from 4 HAPO centers. We will measure blood pressure, adiposity, lipids, glycemia, and lifestyle behaviors, characterize total CVH with AHA's 'Life's Simple 7' framework, and obtain carotid ultrasonography to identify the earliest changes of subclinical CVD. We will also analyze existing cord blood DNAm data and will acquire new epigenome-wide association data from young adult DNA using the Illumina 850K chip.

We will achieve our objectives through the following specific aims:

Specific Aim 1: Define associations of the in utero cardiometabolic milieu at ~28 weeks' gestation with offspring CVH and subclinical CVD in young adulthood.

Hypothesis 1A: Poorer maternal gestational metabolic health is associated with poorer offspring CVH (co-primary outcome) in young adulthood.

Hypothesis 1B: Poorer maternal gestational metabolic health is associated with higher carotid IMT (co-primary outcome), lower carotid distensibility, and unfavorable carotid artery grayscale features in young adulthood.

Hypothesis 1C: Poorer maternal gestational metabolic health is associated with worsening of cardiovascular health from childhood to young adulthood.

Specific Aim 2: Examine the role of epigenetic mechanisms in the association of upstream intrauterine cardiometabolic exposures and downstream CVH and subclinical CVD.

Hypothesis 2A: Poorer maternal gestational metabolic health is associated with differential DNAm in aging-related pathways (measured as accelerated epigenetic aging) in cord blood and young-adult offspring.

Hypothesis 2B: Poorer maternal gestational metabolic health is associated with differential DNAm in specific cardiometabolic pathways in young adult offspring blood cells, and this differential DNAm partly statistically mediates the association of adverse intrauterine exposures with later CVH status and carotid arterial injury in young adulthood.

ANN & Robert H Lurie Childrens Hospital Of Chicago

TO FOSTER HEART AND VASCULAR RESEARCH IN THE BASIC, TRANSLATIONAL, CLINICAL AND POPULATION SCIENCES, AND TO FOSTER TRAINING TO BUILD TALENTED YOUNG INVESTIGATORS IN THESE AREAS, FUNDED THROUGH COMPETITIVE RESEARCH TRAINING GRANTS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, USE SMALL BUSINESS TO MEET FEDERAL RESEARCH AND DEVELOPMENT NEEDS, FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY SOCIALLY AND ECONOMICALLY DISADVANTAGED PERSONS, AND INCREASE PRIVATE-SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE R&D BETWEEN SMALL BUSINESSES AND RESEARCH INSTITUTIONS, AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL R&D.

93.837 - Cardiovascular Diseases Research

National Heart Lung and Blood Institute (NHLBI) [HHS - NIH]

Chicago, Illinois 606112991 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the total obligations have increased 41% from $3,880,806 to $5,472,683.